Illumina, Inc. , a global leader in DNA sequencing and array-based technologies, today announced a pilot proteomics program to analyze 50,000 UK Biobank samples in collaboration with deCODE Genetics, ...

Dupixent® is now used to treat over a million patients globally, with continued growth and expansion in multiple indications for diseases in ...

The chairperson of the Guam Board of Allied Health Examiners on Friday voiced frustration over the licensing process for ...

Kidney cancer therapy candidate, TLX250 (177Lu-girentuximab): The Company was granted a pre-investigational new drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) in Q4 2024, to ...

Benefiting from technological and conceptual groundwork and positive early data, gene therapies are advancing in the clinic ...

Some Bureau De Change operators are still struggling to meet the fresh N2bn recapitalisation threshold of the Central Bank of ...

Market comparables (are your competitors selling for 3x revenues or 12x EBITDA? Are you growing faster than the competition?

In 2024, lung cancer treatment saw significant strides, including the approval of ensartinib for ALK-positive NSCLC and tarlatamab for SCLC. Advances also included December approvals, promising ADC ...

Kemi Badenoch should promise to pull the UK out of the European Convention on Human Rights (ECHR) if the Tories return to ...